Dosing & Uses
Dosage Forms & Strengths
ceftolozane/tazobactam
powder for reconstitution, IV
- 1.5g/vial (ie, 1.5g = 1g ceftolozone plus 0.5g tazobactam)
- Dose is based on the sum of the ingredients
Complicated Intra-abdominal Infections
Indicated for use in combination with metronidazole for complicated intra-abdominal infections (cIAI) cause by Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, and Streptococcus salivarius
1.5 g IV q8hr x4-14 days
Complicated Urinary Tract Infections
Indicated for complicated urinary tract infections (cUTI), including pyelonephritis, caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa
1.5 g IV q8hr x7 days
Bacterial Pneumonia
Indicated for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Serratia marcescens
3 g IV q8hr x8-14 days
Dosage Modifications
Hepatic impairment: No dosage adjustment required
Renal impairment
-
cIAI or cUTI
- CrCl 30-50 mL/min: 750 mg (500 mg/250 mg) IV q8hr
- CrCl 15-29 mL/min: 375 mg (250 mg/125 mg) IV q8hr
- ESRD on hemodialysis: Administer a single loading dose of 750 mg (500 mg/250 mg) followed by a 150-mg (100 mg/50 mg) maintenance dose administered q8hr for the remainder of the treatment period (on hemodialysis days, administer the dose at the earliest possible time following completion of dialysis)
-
HABP/VABP
- CrCl 30-50 mL/min: 1.5 g (1 g/0.5 g) IV q8hr
- CrCl 15-29 mL/min: 750 mg (500 mg/250 mg) IV q8hr
- ESRD on hemodialysis: Administer a single loading dose of 2.25 g (1.5 g/0.75 g) followed by a 450-mg (300 mg/150 mg) maintenance dose administered q8hr for the remainder of the treatment period (on hemodialysis days, administer the dose at the earliest possible time following dialysis completion)
<18 years: Safety and efficacy not established
Adverse Effects
>10% (HABP/VABP)
Increased hepatic transaminase (11.9%)
1-10% (cIAI or cUTI)
Nausea (2.8-7.9%)
Headache (2.5-5.8%)
Diarrhea (1.9-6.2%)
Pyrexia (1.7-5.6%)
Constipation (1.9-3.9%)
Insomnia (1.3-3.5%)
Vomiting (1.1-3.3%)
Hypokalemia (0.8-3.3%)
ALT increased (1.7-1.5%)
AST increased (1-1.7%)
Anemia (0.4-1.5%)
Thrombocytosis (0.4-1.9%)
Abdominal pain (0.8-1.2%)
Anxiety (0.2-1.9%)
Dizziness (0.8-1.1%)
Hypotension (0.4-1.7%)
Atrial fibrillation (0.2-1.2%)
Rash (0.9-1.7%)
1-10% (HABP/VABP)
Renal impairment/failure (8.9%)
Diarrhea (6.4%)
Intracranial hemorrhage (4.4%)
Vomiting (3.3%)
Clostridium difficile colitis (2.8%)
<1%
Cardiac disorders: Tachycardia, angina pectoris
Gastrointestinal disorders: Ileus, gastritis, abdominal distension, dyspepsia, flatulence, paralytic ileus
General disorders and administration site conditions: Infusion site reactions
Infections and infestations: Candidiasis candidiasis (including oropharyngeal and vulvovaginal), fungal urinary tract infection
Investigations: Increased serum gamma-glutamyl transpeptidase (GGT), increased serum alkaline phosphatase, positive Coombs test
Metabolism and nutrition disorders: Hyperglycemia, hypomagnesemia, hypophosphatemia
Nervous system disorders: Ischemic stroke
Renal and urinary system: Renal impairment, renal failure
Respiratory, thoracic, and mediastinal disorders: Dyspnea
Skin and subcutaneous tissue disorders: Urticaria
Vascular disorders: Venous thrombosis
Warnings
Contraindications
Hypersensitivity to any of the components
Cautions
Clinical cure rates lower in patients with baseline CrCl of 30 to ≤50 mL/min when compared with other antibiotics in clinical trials
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions reported with beta-lactam antibacterial agents
As with all antibiotics, Clostridium difficile-associated diarrhea (CDAD) has been reported; if suspected, discontinue and initiate prompt treatment for CDAD
Prescribing antibiotics in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and risks the development of drug-resistant bacteria
Pregnancy & Lactation
Pregnancy
There are no data available on ceftolozane/tazobactam or its individual components regarding use in pregnant women to assess drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes
Human data: Although available studies with multiple cephalosporins cannot definitively establish absence of risk, published data from prospective cohort studies, case series, and case reports over several decades have not identified an association of cephalosporin use during pregnancy with major birth defects, miscarriage, or other adverse maternal or fetal outcomes
Lactation
There are no data on presence of either drug component in human milk; there are no data on effects of either drug component on breastfed infant, or on milk production
Developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from underlying maternal conditions
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Ceftolozane: Cephalosporin that has demonstrated potent in vitro activity against Pseudomonas aeruginosa
Tazobactam: Beta-lactamase inhibitor
Absorption
Day 1 measurements
Peak plasma time: 1.02 hr
Peak plasma concentration: 65.7/17.8 mcg/mL (cIAI, cUTI); 105/26.4 mcg/mL (HABP/VABP)
AUC: 186/35.8 mcg•h/mL (cIAI, cUTI); 392/73.3 mcg•h/mL (HABP/VABP)
Distribution
Protein bound: 16-21/30%
Vd: 13.5/18.2 L
Metabolism
Ceftolozane: Not metabolized to any appreciable extent
Tazobactam: The beta-lactam ring is hydrolyzed to form the pharmacologically inactive tazobactam metabolite M1
Elimination
Half-life: 2.77/0.91 hr
Renal clearance (ceftolozane): 3.41-5.59 L/hr
Excretion
- Ceftolozane: >95% excreted unchanged in urine
- Tazobactam: >80% excreted as the parent compound with the remainder excreted as the M1 metabolite
Administration
IV Compatibilities
Not established
IV Preparation
Reconstitute vial with 10 mL of sterile water for injection or 10 mL 0.9% NaCl and gently shake to dissolve
Final volume is ~11.4 mL
Must be further diluted; reconstituted solution is NOT for direct injection
Withdraw appropriate volume for dose (see list below) and add to 100 mL of 0.9% NaCl or D5W
Inspect for particulate matter and discoloration; color ranges from clear, colorless solutions to solutions that are clear and slightly yellow
Dose volume
- 3 g (2 g/1 g): 2 vials of 11.4 mL each (entire contents from 2 vials)
- 2.25 g (1.5 g/0.5 g): 11.4 mL from 1 vial (entire contents) and 5.7 mL from a second vial
- 1.5 g (1 g/0.5 g): 11.4 mL (entire vial contents)
- 750 mg (500 mg/250 mg): 5.7 mL
- 450 mg (300 mg/150 mg): 3.5 mL
- 375 mg (250 mg/125 mg): 2.9 mL
- 150 mg (100 mg/50 mg): 1.2 mL
IV Administration
Infuse IV over 1 hr
Storage
Unreconstituted vials: Store refrigerated 2-8°C (36-46°F); protect from light
Reconstituted vials: May keep at room temperature for 1 hr before transfer and dilution in infusion bag
Diluted solution (IV bag): Stable for 24 hr when stored at room temperature or 7 days when refrigerated at 2-8°C (36-46°F)
Do not freeze
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.